287 related articles for article (PubMed ID: 11109640)
81. Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States.
Ishigami J; Padula WV; Grams ME; Chang AR; Jaar B; Gansevoort RT; Bridges JFP; Kovesdy CP; Uchida S; Coresh J; Matsushita K
Am J Kidney Dis; 2019 Jul; 74(1):23-35. PubMed ID: 30898360
[TBL] [Abstract][Full Text] [Related]
82. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
83. [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
Qiu YP; Zhao K; Li X; Shi LW; Guo WD; Qi XR; Sui BY; Zhou RM
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1074-1078. PubMed ID: 28057111
[No Abstract] [Full Text] [Related]
84. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
85. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
86. Cost-effectiveness analysis of pneumococcal vaccination for infants in China.
Maurer KA; Chen HF; Wagner AL; Hegde ST; Patel T; Boulton ML; Hutton DW
Vaccine; 2016 Dec; 34(50):6343-6349. PubMed ID: 27810315
[TBL] [Abstract][Full Text] [Related]
87. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
[TBL] [Abstract][Full Text] [Related]
88. [Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain)].
Plans P
Gac Sanit; 2002; 16(5):392-400. PubMed ID: 12372184
[TBL] [Abstract][Full Text] [Related]
89. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
[TBL] [Abstract][Full Text] [Related]
90. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales.
Melegaro A; Edmunds WJ
Eur J Epidemiol; 2004; 19(4):365-75. PubMed ID: 15180107
[TBL] [Abstract][Full Text] [Related]
91. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium.
Blommaert A; Bilcke J; Vandendijck Y; Hanquet G; Hens N; Beutels P
Vaccine; 2014 Oct; 32(46):6075-83. PubMed ID: 25239481
[TBL] [Abstract][Full Text] [Related]
92. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.
Smith KJ; Zimmerman RK; Lin CJ; Nowalk MP; Ko FS; McEllistrem MC; Roberts MS
Vaccine; 2008 Mar; 26(11):1420-31. PubMed ID: 18272262
[TBL] [Abstract][Full Text] [Related]
93. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2019 Mar; 37(14):2026-2033. PubMed ID: 30846259
[TBL] [Abstract][Full Text] [Related]
94. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
[TBL] [Abstract][Full Text] [Related]
95. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany.
Claes C; Graf von der Schulenburg JM
Pharmacoeconomics; 2003; 21(8):587-600. PubMed ID: 12751916
[TBL] [Abstract][Full Text] [Related]
96. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.
Prosser LA; Ray GT; O'Brien M; Kleinman K; Santoli J; Lieu TA
Pediatrics; 2004 Feb; 113(2):283-90. PubMed ID: 14754939
[TBL] [Abstract][Full Text] [Related]
97. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2013 Jun; 31(25):2762-71. PubMed ID: 23588088
[TBL] [Abstract][Full Text] [Related]
98. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China.
Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y
Front Public Health; 2021; 9():647725. PubMed ID: 34109145
[No Abstract] [Full Text] [Related]
99. Evaluating the costs and benefits of pneumococcal vaccination in adults.
Porchia BR; Bonanni P; Bechini A; Bonaccorsi G; Boccalini S
Expert Rev Vaccines; 2017 Feb; 16(2):93-107. PubMed ID: 27680425
[TBL] [Abstract][Full Text] [Related]
100. Determining the cost-effectiveness of adult pneumococcal vaccination strategies.
Smith KJ
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):1-4. PubMed ID: 24329002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
